Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Renograf** appears to refer to a historical brand of **diatrizoate-based iodinated radiographic contrast medium**, most plausibly within the Renografin product family. Diatrizoate salts are **ionic, high-osmolar triiodinated benzoic acid derivatives** used as X-ray contrast agents; they do not act through a receptor-mediated pharmacologic target, but instead increase radiographic attenuation because of their high iodine content, thereby enhancing visualization of structures such as the urinary tract and vasculature during diagnostic imaging. Available evidence suggests the queried name is not well standardized in current labeling and may represent a variant, shorthand, or misspelling related to Renografin products rather than a distinct modern drug entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renograf.